Amgen Inc (AMGN) operating KPIs
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)
Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%
Amgen vectibix (panitumumab — Metastatic Colorectal Cancer) — Worldwide volume growth YoY (%) (%)
Form 8-K Product Sales Performance & Form 10-Q / 10-K MD&A
Latest, FY2024
4.0%
Period ended Dec 31, 2024
Change on a year earlier
-6.0 pts
10.0% in FY2023
History
2 years
Since FY2023
Sources
2
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Vectibix (panitumumab — Metastatic Colorectal Cancer) — Worldwide volume growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2024 | Dec 31, 2024 | 4.0% | -6.0 pts | Form 8-K (amgn-20241231earningsrelea.htm, filed 2025-02-04) ↗ |
| FY2023 | Dec 31, 2023 | 10.0% | – | Form 8-K (amgn-20231231earningsrelea.htm, filed 2024-02-06) ↗ |
Cite this data
StockData. (2026). Amgen Vectibix (panitumumab — Metastatic Colorectal Cancer) — Worldwide volume growth YoY (%) (%), annual FY2023–FY2024 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod_vectibix_vol
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.